Panbela Therapeutics, Inc. (PBLA)
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Address
712 VISTA BLVD #305
WACONIA, MN 55387
Founded
2011
Number of Employees
7
Website
http://www.panbela.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)